| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40261-013-0052-6 |
| P698 | PubMed publication ID | 23338974 |
| P2093 | author name string | Jorge Pinto Pereira Barbosa | |
| José Pedro Henriques Patrício | |||
| Nuno Filipe Pimenta Antunes | |||
| Pedro Carlos Santos de Melo | |||
| Rui Miguel Monteiro Ramos | |||
| P2860 | cites work | Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis | Q43248977 |
| Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. | Q44295966 | ||
| Characterization of etoricoxib, a novel, selective COX-2 inhibitor | Q44484802 | ||
| Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. | Q45258184 | ||
| Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. | Q45917871 | ||
| Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. | Q45940021 | ||
| Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population | Q46257782 | ||
| Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Ag | Q46317678 | ||
| Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). | Q46927526 | ||
| Uso apropiado de los antiinflamatorios no esteroideos en reumatología: documento de consenso de la Sociedad Española de Reumatología y el Colegio Mexicano de Reumatología | Q56966882 | ||
| Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences | Q61906523 | ||
| Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial | Q73423989 | ||
| Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs | Q74576738 | ||
| Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults | Q79526736 | ||
| Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident | Q80085198 | ||
| Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model | Q82704671 | ||
| Using NSAIDs in cardiovascular disease | Q83119116 | ||
| Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself? | Q22306448 | ||
| Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population | Q24816136 | ||
| Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. | Q27863328 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy | Q28166768 | ||
| Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects | Q28174152 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs | Q28191928 | ||
| Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study | Q28195282 | ||
| Celecoxib for the prevention of colorectal adenomatous polyps | Q28200375 | ||
| Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) | Q28210559 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial | Q28211435 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q28218927 | ||
| NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies | Q28742977 | ||
| Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| A review of the gastrointestinal safety data--a gastroenterologist's perspective | Q33560647 | ||
| Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine | Q33684722 | ||
| Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis | Q33871754 | ||
| Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study | Q33941101 | ||
| Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery | Q33985078 | ||
| Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals | Q34119616 | ||
| Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study | Q34323910 | ||
| Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. | Q34534906 | ||
| Prostaglandins in health and disease: an overview | Q34554050 | ||
| Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. | Q34575707 | ||
| Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association | Q34576407 | ||
| Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 | ||
| Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis | Q34610283 | ||
| Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. | Q34621619 | ||
| Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure | Q34930633 | ||
| A trial of adjuvant therapy in colorectal cancer: the VICTOR trial | Q35141210 | ||
| Etoricoxib for arthritis and pain management | Q35166773 | ||
| Cyclooxygenase inhibition and cardiovascular risk | Q36215336 | ||
| Harmful effects of NSAIDs among patients with hypertension and coronary artery disease | Q36332332 | ||
| Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? | Q36645806 | ||
| COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs | Q37061134 | ||
| Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly | Q37209605 | ||
| Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials | Q37257464 | ||
| Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications | Q37484552 | ||
| Long-term safety concerns with proton pump inhibitors | Q37604552 | ||
| Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract | Q37708639 | ||
| The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. | Q37787639 | ||
| NSAID-induced gastrointestinal and cardiovascular injury | Q37800342 | ||
| Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials | Q37862577 | ||
| Stroke risk and NSAIDs: a systematic review of observational studies | Q37942486 | ||
| Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial | Q39284689 | ||
| Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study | Q39379167 | ||
| Is the WHO analgesic ladder still valid? Twenty-four years of experience. | Q42734195 | ||
| NSAID prescribing precautions | Q43226347 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 167-183 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice | |
| P478 | volume | 33 |
| Q87319153 | Antiplatelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit |
| Q24186992 | Aspirin and anti-inflammatory drugs for the prevention of dementia |
| Q87845127 | Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study |
| Q58579972 | Diabetic Retinopathy: A complex pathophysiology requiring novel therapeutic strategies |
| Q49334912 | Effects of flurbiprofen on serum level of interleukin-6, prostacyclin and corticosteroid A2 in patients with bone metastases of cancer |
| Q38447864 | Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation |
| Q28078199 | Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy |
| Q41360072 | NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain |
| Q40138226 | NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications |
| Q39356641 | Pharmacological evaluation and preparation of nonsteroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit |
| Q42969469 | Polyp Clearance via Operative and Endoscopic Polypectomy in Patients With Peutz-Jeghers Syndrome After Multiple Small Bowel Resections |
| Q99238880 | Prevalence of Gastrointestinal and Cardiovascular Risk in Patients with Degenerative Lumbar Spinal Disease |
Search more.